B. Riley reissued their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report sent to investors on Thursday morning, TipRanks reports. They currently have a $12.00 price target on the biotechnology company’s stock.
VKTX has been the topic of several other reports. Maxim Group assumed coverage on shares of Viking Therapeutics in a report on Saturday, May 2nd. They set a buy rating and a $14.00 price target on the stock. William Blair reaffirmed a buy rating on shares of Viking Therapeutics in a report on Friday, April 3rd. BMO Capital Markets assumed coverage on shares of Viking Therapeutics in a report on Thursday, June 4th. They set an outperform rating and a $14.00 price target on the stock. BidaskClub lowered shares of Viking Therapeutics from a hold rating to a sell rating in a report on Wednesday, July 15th. Finally, Stifel Nicolaus reaffirmed a buy rating and set a $14.00 price target on shares of Viking Therapeutics in a report on Wednesday. One research analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $14.78.
Shares of NASDAQ:VKTX opened at $7.02 on Thursday. The firm has a 50 day moving average of $7.11 and a 200-day moving average of $6.41. Viking Therapeutics has a 12 month low of $3.26 and a 12 month high of $8.87.
Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. As a group, research analysts expect that Viking Therapeutics will post -0.6 EPS for the current year.
In other Viking Therapeutics news, Director Matthew W. Foehr sold 13,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $7.35, for a total transaction of $95,550.00. Following the sale, the director now directly owns 26,250 shares of the company’s stock, valued at approximately $192,937.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.70% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada grew its holdings in Viking Therapeutics by 3.7% during the 1st quarter. Royal Bank of Canada now owns 47,655 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 1,693 shares during the last quarter. Brinker Capital Inc. boosted its stake in shares of Viking Therapeutics by 6.1% in the 2nd quarter. Brinker Capital Inc. now owns 31,712 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 1,811 shares during the last quarter. Creative Planning boosted its stake in shares of Viking Therapeutics by 7.6% in the 1st quarter. Creative Planning now owns 42,573 shares of the biotechnology company’s stock valued at $199,000 after purchasing an additional 3,000 shares during the last quarter. Verus Capital Partners LLC bought a new stake in shares of Viking Therapeutics in the 4th quarter valued at $26,000. Finally, Great West Life Assurance Co. Can bought a new stake in shares of Viking Therapeutics in the 4th quarter valued at $30,000. 54.21% of the stock is currently owned by hedge funds and other institutional investors.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis.
Featured Article: What does a market perform rating mean?
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.